Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, and Ocular Oncology and Treatments.
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial
Low-Dose Total Skin Electron Beam Radiotherapy in Stage IB-IIB Mycosis Fungoides: Results From the Prospective S-MISR Study
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status
Crosstalk between CLL and cutaneous T-cell lymphoma: MIF-CD74 axis and dysregulated inflammatory signaling
Melanoma of the Choroid and Ciliary Body in Children: Remission of Metastatic Melanoma of the Choroid After Treatment With Chemotherapy and Immune Checkpoint Inhibition
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Real‐world management of patients with complete response under immune‐checkpoint inhibition for advanced melanoma
Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Health‐related quality of life and its influencing factors in patients with primary cutaneous B‐cell lymphomas: A multicentric study in 100 patients
Spontaneous regression of primary cutaneous diffuse large B‐cell lymphoma, leg type: A case series and review of the literature
Psychosocial distress and psychosocial resources in couples facing non-melanoma skin cancers and malignant melanoma
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
1124P Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study
PTHrP-induced hypercalcemic psychosyndrome under combined anti-PD-L1 and anti-EGFR inhibition in penile squamous cell carcinoma – A case report
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
Characterisation and outcome of RAC1 mutated melanoma
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG